Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ReveraGen
ReveraGen
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
Thu, 03/16/23 - 09:49 am
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Wed, 02/22/23 - 10:00 am
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
Pharmaceutical Business Review
Tue, 01/10/23 - 10:42 am
Santhera Pharmaceuticals
ReveraGen
vamorolone
Duchenne Muscular Dystrophy
FDA
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Wed, 09/2/20 - 11:04 am
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen